Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.

[1]  P. Carmeliet,et al.  Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. , 2014, Cell metabolism.

[2]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[3]  G. Pagès,et al.  Mechanisms of resistance to anti-angiogenesis therapies. , 2013, Biochimie.

[4]  M. Tan,et al.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. , 2013, Cancer research.

[5]  R. Jeraj,et al.  A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies , 2011, Cancer Chemotherapy and Pharmacology.

[6]  A. Noel,et al.  Targeting the tumor microenvironment for cancer therapy. , 2013, Clinical chemistry.

[7]  I. Kasman,et al.  Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models , 2012, The Journal of pathology.

[8]  J. Erler,et al.  Contrasting effects of sunitinib within in vivo models of metastasis , 2012, Angiogenesis.

[9]  E. Jonasch,et al.  Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients , 2012, Clinical Cancer Research.

[10]  Barbara Sennino,et al.  Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. , 2012, Cancer discovery.

[11]  R. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[12]  M. V. Vander Heiden.  Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[13]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[15]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[16]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[17]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[18]  J. Haanen,et al.  Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response , 2008, Clinical Cancer Research.

[19]  A. Kudelka,et al.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.

[20]  M. Leggas,et al.  Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. , 2007, Clinical therapeutics.

[21]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[22]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[23]  Dirk Strumberg,et al.  Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. , 2005, Drugs of today.

[24]  K. Chikuni,et al.  Extracellular matrix development during differentiation into adipocytes with a unique increase in type V and VI collagen , 2002, Biology of the cell.

[25]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  J. Foidart,et al.  Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. , 1993, British Journal of Cancer.